|
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. Brünnert D, Kraus M, Stühmer T, Kirner S, Heiden R, Goyal P, Driessen C, Bargou RC, Chatterjee M. Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1666-1676. doi: 10.1016/j.bbadis.2019.04.003. Epub 2019 Apr 4.
|
|
Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities. Memmel S, Sisario D, Zöller C, Fiedler V, Katzer A, Heiden R, Becker N, Eing L, Ferreira FLR, Zimmermann H, Sauer M, Flentje M, Sukhorukov VL, Djuzenova CS. Oncotarget. 2017 Jul 11;8(28):45298-45310. doi: 10.18632/oncotarget.16847.Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities. Memmel S, Sisario D, Zöller C, Fiedler V, Katzer A, Heiden R, Becker N, Eing L, Ferreira FLR, Zimmermann H, Sauer M, Flentje M, Sukhorukov VL, Djuzenova CS. Oncotarget. 2017 Jul 11;8(28):45298-45310. doi: 10.18632/oncotarget.16847.
|